Close Menu

NEW YORK (GenomeWeb) – Two recently published sequencing methods demonstrate the ability to systematically reveal unintended consequences of CRISPR/Cas9 activity in the genome.

The methods could provide researchers with an accurate and unbiased tool to gauge the specificity of the gene editing technology as it moves closer toward clinical therapeutic use, according to experts.

The ability of the Cas9 nuclease to create a double-stranded break is the crux of CRISPR, but scientists have been reporting off-target effects and have to design their experiments to account for it.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.

Jul
09
Sponsored by
Illumina

In this webinar, Dr. Charlie Johnson, founder of the Texas A&M AgriLife Genomics and Bioinformatics Service, will share how his team is utilizing Illumina’s DRAGEN informatics platform in its high-throughput agrigenomics research program. 

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
16
Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
22
Sponsored by
Thermo Fisher Scientific

Luis A. Alcaraz, cofounder of Bioarray and Journey Genomics, accredited diagnostic and research labs based in Alicante, Spain, will review how his teams use advanced genomic techniques for carrier screening research as well as for preimplantation genetic testing (PGT) in embryos for both aneuploidies (PGT-A) and monogenic disorders (PGT-M).